fig3

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Figure 3. Intrinsic resistance mechanisms affecting tyrosine kinase inhibitor activity in RCC. Bcl-2: B cell lymphoma-2; Bcl-xL: B cell lymphoma-extra large; EZH2: enhancer of zeste homolog 2; PRC2: polycomb repressive complex 2; RCC: renal cell carcinoma.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/